
	<!DOCTYPE html>
	<html>
		<head>
			<title>【国金医药】键凯科技：半年报业绩表现靓丽，创新研发持续赋能！</title>
			<meta charset="utf-8" />
		</head>
		<body>
			<div class="note-wrapper">
				<h1>【国金医药】键凯科技：半年报业绩表现靓丽，创新研发持续赋能！</h1>
				<button class="btn btn-primary"><a href="../index.html">返回主页</a></button><br><br>
				【国金医药】键凯科技：半年报业绩表现靓丽，创新研发持续赋能！<br><br>8月25日，键凯科技发布2022年中报，公司2022H1实现营业收入2.15亿元，同比增长37.91%；归母净利润1.11亿元，同比增长38.15%；扣非后归母净利润0.96亿元，同比增长23.95%。单二季度，公司实现营业收入1.14亿元，同比增长32.75%；归母净利润0.59亿元，同比增长32.30%。<br>分地区看，内销收入0.77亿元，同比增长45.21%；外销收入1.10亿元，同比增长26.06%。国内产品销售收入的增长，系国内下游主要客户上市产品销售持续放量带来订单量的增加；国外产品销售收入的增长，系国外医疗器械端产品订单的稳定增长，以及海外下游医药研发客户临床研发进度推进带来的产品用量增加所带来的增长。<br>先行指标向好，公司有望持续高增长。从存货指标看看，公司22H1末0.50亿，同比增长19.97%，主要系公司销售订单增加，订单备货增加；在建工程0.96亿，同比增长11.21%；已签订合同、但尚未履行或尚未履行完毕的履约义务金额约为2.78亿元，均将在下半年确认收入。<br>研发持续高投入。22H1公司研发合计投入0.42亿元，同比增长136.82%。公司持续加大对自主研究开发的聚乙二醇伊立替康、JK-2122H和JK-1119I项目的推进，并同时积极布局其他研发管线，在研发人才、物料和设备等方面持续投入。目前，公司已在肿瘤治疗、局部止痛、生物免疫抑制及医疗美容等领域研发了聚乙二醇伊立替康、JK-2122H、JK-1119I等数个在研产品。上述自主开发的聚乙二醇修饰药物及第三类医疗器械中，聚乙二醇伊立替康已进入II期临床阶段，医疗器械项目JK-2122H已进入临床阶段<br>欢迎交流。<br>（国金医药 王班、杨馥瑗）<br><br>#文字纪要#
				<br><br><button class="btn btn-primary"><a href="../index.html">返回主页</a></button>
	
			</div>
			<script type="text/javascript">
				(function() {
	
		var doc_ols = document.getElementsByTagName("ol");
	
		for ( i=0; i<doc_ols.length; i++) {
	
			var ol_start = doc_ols[i].getAttribute("start") - 1;
			doc_ols[i].setAttribute("style", "counter-reset:ol_counter " + ol_start + ";");
	
		}
	
	})();
	
			</script>
			<style>
				html,body,div,span,applet,object,iframe,h1,h2,h3,h4,h5,h6,p,blockquote,pre,a,abbr,acronym,address,big,cite,code,del,dfn,em,img,ins,kbd,q,s,samp,small,strike,strong,sub,sup,tt,var,b,u,i,center,dl,dt,dd,ol,ul,li,fieldset,form,label,legend,table,caption,tbody,tfoot,thead,tr,th,td,article,aside,canvas,details,embed,figure,figcaption,footer,header,hgroup,menu,nav,output,ruby,section,summary,time,mark,audio,video{margin:0;padding:0;border:0;font:inherit;font-size:100%;vertical-align:baseline}html{line-height:1}ol,ul{list-style:none}table{border-collapse:collapse;border-spacing:0}caption,th,td{text-align:left;font-weight:normal;vertical-align:middle}q,blockquote{quotes:none}q:before,q:after,blockquote:before,blockquote:after{content:"";content:none}a img{border:none}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}*{-moz-box-sizing:border-box;-webkit-box-sizing:border-box;box-sizing:border-box}html{font-size:87.5%;line-height:1.57143em}html{font-size:14px;line-height:1.6em;-webkit-text-size-adjust:100%}body{background:#fcfcfc;color:#545454;text-rendering:optimizeLegibility;font-family:"AvenirNext-Regular"}a{color:#de4c4f;text-decoration:none}h1{font-family:"AvenirNext-Medium";color:#333;font-size:1.6em;line-height:1.3em;margin-bottom:.78571em}h2{font-family:"AvenirNext-Medium";color:#333;font-size:1.3em;line-height:1em;margin-bottom:.62857em}h3{font-family:"AvenirNext-Medium";color:#333;font-size:1.15em;line-height:1em;margin-bottom:.47143em}p{margin-bottom:1.57143em;hyphens:auto}hr{height:1px;border:0;background-color:#dedede;margin:-1px auto 1.57143em auto}ul,ol{margin-bottom:.31429em}ul ul,ul ol,ol ul,ol ol{margin-bottom:0px}ol{counter-reset:ol_counter}ol li:before{content:counter(ol_counter) ".";counter-increment:ol_counter;color:#e06e73;text-align:right;display:inline-block;min-width:1em;margin-right:0.5em}b,strong{font-family:"AvenirNext-Bold"}i,em{font-family:"AvenirNext-Italic"}code{font-family:"Menlo-Regular"}.text-overflow-ellipsis{overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.sf_code_string,.sf_code_selector,.sf_code_attr-name,.sf_code_char,.sf_code_builtin,.sf_code_inserted{color:#D33905}.sf_code_comment,.sf_code_prolog,.sf_code_doctype,.sf_code_cdata{color:#838383}.sf_code_number,.sf_code_boolean{color:#0E73A2}.sf_code_keyword,.sf_code_atrule,.sf_code_rule,.sf_code_attr-value,.sf_code_function,.sf_code_class-name,.sf_code_class,.sf_code_regex,.sf_code_important,.sf_code_variable,.sf_code_interpolation{color:#0E73A2}.sf_code_property,.sf_code_tag,.sf_code_constant,.sf_code_symbol,.sf_code_deleted{color:#1B00CE}.sf_code_macro,.sf_code_entity,.sf_code_operator,.sf_code_url{color:#920448}.note-wrapper{max-width:46em;margin:0px auto;padding:1.57143em 3.14286em}.note-wrapper.spotlight-preview{overflow-x:hidden}u{text-decoration:none;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#e06e73 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}s{color:#878787}p{margin-bottom:0.1em}hr{margin-bottom:0.7em;margin-top:0.7em}ul li{text-indent:-0.35em}ul li:before{content:"•";color:#e06e73;display:inline-block;margin-right:0.3em}ul ul{margin-left:1.25714em}ol li{text-indent:-1.45em}ol ol{margin-left:1.25714em}blockquote{display:block;margin-left:-1em;padding-left:0.8em;border-left:0.2em solid #e06e73}.todo-list ul{margin-left:1.88571em}.todo-list li{text-indent:-1.75em}.todo-list li:before{content:"";display:static;margin-right:0px}.todo-checkbox{text-indent:-1.7em}.todo-checkbox svg{margin-right:0.3em;position:relative;top:0.2em}.todo-checkbox svg #check{display:none}.todo-checkbox.todo-checked #check{display:inline}.todo-checkbox.todo-checked+.todo-text{text-decoration:line-through;color:#878787}.code-inline{display:inline;background:white;border:solid 1px #dedede;padding:0.2em 0.5em;font-size:0.9em}.code-multiline{display:block;background:white;border:solid 1px #dedede;padding:0.7em 1em;font-size:0.9em;overflow-x:auto}.hashtag{display:inline-block;color:white;background:#b8bfc2;padding:0.0em 0.5em;border-radius:1em;text-indent:0}.hashtag a{color:#fff}.address a{color:#545454;background-image:linear-gradient(to bottom, rgba(0,0,0,0) 50%,#0da35e 50%);background-repeat:repeat-x;background-size:2px 2px;background-position:0 1.05em}.address svg{position:relative;top:0.2em;display:inline-block;margin-right:0.2em}.color-preview{display:inline-block;width:1em;height:1em;border:solid 1px rgba(0,0,0,0.3);border-radius:50%;margin-right:0.1em;position:relative;top:0.2em;white-space:nowrap}.color-code{margin-right:0.2em;font-family:"Menlo-Regular";font-size:0.9em}.color-hash{opacity:0.4}.ordered-list-number{color:#e06e73;text-align:right;display:inline-block;min-width:1em}.arrow svg{position:relative;top:0.08em;display:inline-block;margin-right:0.15em;margin-left:0.15em}.arrow svg #rod{stroke:#545454}.arrow svg #point{fill:#545454}mark{color:inherit;display:inline;padding:0.2em 0.5em;background-color:#fcffc0}img{max-width:100%;height:auto}
			</style>
		</body>
	</html>
	